Citations

Clear

40 citation(s) found for "Sinclair, Rd".

ST-elevation myocardial infarction after thrombolytic therapy with Tenecteplase for acute ischaemic stroke
FRÍAS, JORGE SINCLAIR DE , Harrison, Michael F. , Sanghavi, Devang , Sinclair, Jorge Enrique , Plante, Marie, Sanghavi, Devang K., Plante, Marie

Mayo Clinic

BMJ Case Reports | June 14, 2023 | Volume: 16 | Issue: 6 | Pages: e252253

10.1136/bcr-2022-252253 | PMID 37316282 Get It

Myocardial infarction (MI) secondary to thrombolytic therapy in the setting of acute ischaemic stroke (AIS) is a rare but severe complication. This phenomenon has been well documented in the past with recombinant tissue-type plasminogen activator, also known as Alteplase. However, there are no documented reports of MI secondary to Tenecteplase (TNKase), an alternative thrombolytic agent rapidly gaining favour in managing AIS. We report a male patient in his 50s who received TNKase for an AIS and subsequently developed an inferolateral ST elevation MI.
2023 HRS/EHRA/APHRS/LAHRS Expert Consensus Statement on Practical Management of the Remote Device Clinic
Ferrick, Aileen M., Kojodjojo, Pipin , López-Cabanillas, Néstor , Chew, Derek S. , Choi, Jong‐Il , Dagres, Nikolaos , Dalal, Aarti , Dechert, Brynn E. , Frazier‐Mills, Camille, Gilbert, Olivia , Hewit, Sherri, Kneeland, Christine , Mirza, Starr DeEllen, Runté, Mary, Sinclair, Susan, Teixeira, Ricardo Alkmim , Vandenberk, Bert , Davenport, Elizabeth , Freedenberg, Vicki , Glotzer, Taya V. , Ikeda, Takanori , Kramer, Daniel B. , Lin, David , Rojel-Martínez, Ulises, Stühlinger, Markus , Varosy, Paul D. , Dagres, Nikolaos , Raj, Satish R , Deneke, Thomas , Abe, Haruhiko , Bovéda, Serge , Han, Janet K. , Hewit, Sherri, Mittal, Suneet , Ricci, Renato Pietro , Teixeira, Ricardo Alkmim , Vandenberk, Bert , Varma, Niraj , Huang, Jin‐Long

Mayo Clinic

Europace | May 20, 2023 | Volume: 25 | Issue: 5 | Pages: No page available

10.1093/europace/euad123 | PMID 37208301 Get It

Abstract Remote monitoring is beneficial for the management of patients with cardiovascular implantable electronic devices by impacting morbidity and mortality. With increasing numbers of patients using remote monitoring, keeping up with higher volume of remote monitoring transmissions creates challenges for device clinic staff. This international multidisciplinary document is intended to guide cardiac electrophysiologists, allied professionals, and hospital administrators in managing remote monitoring clinics. This includes guidance for remote monitoring clinic staffing, appropriate clinic workflows, patient education, and alert management. This expert consensus statement also addresses other topics such as communication of transmission results, use of third-party resources, manufacturer responsibilities, and programming concerns. The goal is to provide evidence-based recommendations impacting all aspects of remote monitoring services. Gaps in current knowledge and guidance for future research directions are also identified.
2023 HRS/EHRA/APHRS/LAHRS Expert Consensus Statement on Practical Management of the Remote Device Clinic
Ferrick, Aileen M., Kojodjojo, Pipin , López-Cabanillas, Néstor , Chew, Derek S. , Choi, Jong‐Il , Dagres, Nikolaos , Dalal, Aarti , Dechert, Brynn E. , Frazier‐Mills, Camille, Gilbert, Olivia , Hewit, Sherri, Kneeland, Christine , Mirza, Starr DeEllen, Runté, Mary, Sinclair, Susan, Teixeira, Ricardo Alkmim , Vandenberk, Bert , Reviewers, Document, Davenport, Elizabeth , Freedenberg, Vicki , Glotzer, Taya V. , Ikeda, Takanori , Kramer, Daniel B. , Lin, David , Rojel‐Martínez, Ulises, Stühlinger, Markus , Varosy, Paul D. , Huang, Jin-Long, Rojel-Martínez, Ulises, Dagres, Nikolaos , Raj, Satish R , Deneke, Thomas , Abe, Haruhiko , Bovéda, Serge , Han, Janet K. , Mittal, Suneet , Ricci, Renato Pietro , Teixeira, Ricardo Alkmim , Vandenberk, Bert , Varma, Niraj , Reviewers, Document, Huang, Jin‐Long

Mayo Clinic

Journal of Arrhythmia | May 19, 2023 | Volume: 39 | Issue: 3 | Pages: 250-302

10.1002/joa3.12851 | PMID 37324757 Get It

AbstractRemote monitoring is beneficial for the management of patients with cardiovascular implantable electronic devices by impacting morbidity and mortality. With increasing numbers of patients using remote monitoring, keeping up with higher volume of remote monitoring transmissions creates challenges for device clinic staff. This international multidisciplinary document is intended to guide cardiac electrophysiologists, allied professionals, and hospital administrators in managing remote monitoring clinics. This includes guidance for remote monitoring clinic staffing, appropriate clinic workflows, patient education, and alert management. This expert consensus statement also addresses other topics such as communication of transmission results, use of third‐party resources, manufacturer responsibilities, and programming concerns. The goal is to provide evidence‐based recommendations impacting all aspects of remote monitoring services. Gaps in current knowledge and guidance for future research directions are also identified.
Clinical Features of Pneumothorax, Pneumomediastinum, and Subcutaneous Emphysema in Hospitalized COVID-19 Patients
Frias, J.E. Sinclair De, Baptista, A. Murawska, Singh, Tarun D. , VASUDHAR, ANANYA, Gavrancic, Tatjana , Lewis, Patricia , Sanghavi, Devang , Vasudhar, Ananya, Joyce, W., Lewis, P., Franco, Pablo Moreno

Mayo Clinic

C45. COVID AND ITS CONSEQUENCES: PART II | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A5138-A5138

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5138 Get It

Local Infiltration of Tranexamic Acid During Facelift Improves Operating Room Efficiency: A Matched Patient Study
Coombs, Demetrius M. , Kwiecień, Grzegorz , Sinclair, Nicholas R , Jin, Alison , Zins, James E. , Kwiecien, Grzegorz J

Mayo Clinic

Aesthetic Surgery Journal | March 29, 2022 | Volume: 42 | Issue: 9 | Pages: 971-977

10.1093/asj/sjac067 | PMID 35350068 Get It

Abstract Background Tranexamic acid (TXA) has rapidly gained popularity in aesthetic surgery. Previous reports have suggested that TXA provides a dry surgical field and significantly reduces operating time during facelift surgery. Objectives The aim of this study was to build upon earlier findings by providing a large cohort matched alongside historic controls and more clearly document time saved when performing facelift surgery. Methods A retrospective, single-surgeon case-control study was undertaken between July 2016 and October 2021. All patients underwent facelift surgery alone or in combination with fat transfer and perioral chemical peel. All patients received subcutaneous infiltration of 0.5% lidocaine/1:200,000 epinephrine with or without 1 or 2 mg/mL TXA. Patient demographics, TXA dose, surgical time, and minor and major complications were examined. Results In total 145 consecutive patients were identified: 73 in Group 1 (no-TXA) and 72 in Group 2 (TXA). No differences in terms of gender distribution (P = 0.75), age (P = 0.54), BMI (P = 0.18), frequency of secondary rhytidectomy (P = 0.08), rate of ancillary lipografting (P = 0.44), TXA dose (P = 0.238), and minor complication rate (P = 0.56) were observed. However, mean surgical time in the no-TXA group was 21 minutes longer than in the TXA group (P = 0.016). Six patients (8%) in the no-TXA group experienced minor complications vs 8 patients (11%) in the TXA group. No patients experienced major complications. Conclusions Although previous studies have highlighted the potential benefits of TXA in aesthetic surgery, most of the data remain subjective and non-validated. This report adds to the objective body of evidence supporting TXA in facial aesthetic surgery by documenting time saved in the operating room without additional surgical morbidity. Level of Evidence: 4
Meeting Report: Aging Research and Drug Discovery
Meron, Esther, Thaysen, Maria, Antebi, Adam , Barzilai, Nir , Birkisdóttir, María B. , Bruening, Jens, Brunet, Anne , Cai, Shi‐Qing , Chen, Brian H. , Ermolaeva, Maria , Ewald, Collin Y. , Ferrucci, Luigi , Fortney, Kristen , Freund, Adam , Georgievskaya, Anastasia , Gladyshev, Vadim N. , Golato, Tyler, Hoejimakers, Jan, Houtkooper, Riekelt H. , Jaksch, Frank, Janssens, Georges E. , Jensen, Martin Borch , Kirkland, James L. , Kjær, Michael , Lee, Kai-Fu, Lemaı̂tre, Jean-Marc , Liaskos, David, Longo, Valter D. , Lu, Yuxuan , MacArthur, Michael R. , Maier, Andrea B. , Manakanatas, Christina, Mitchell, Sarah J. , Moskalev, Alexey , Niedernhofer, Laura J. , Ozerov, Ivan V. , Peyer, James , Radenković, Dina , Rattan, Suresh I. S. , Riedel, Christian G. , Schumacher, Björn , Smith, Ryan , Suh, Yousin , Trapp, Alexandre , Trendelenburg, Anne‐Ulrike, Valenzano, Dario Riccardo , Verburgh, Kris, Zhavoronkov, Alex , Niedernhofer, Laura J , Ferrucci, Luigi , Gladyshev, Vadim N , Thaysen, Maria , Angeli, Suzanne , Baur, Joseph A. , Bekker‐Jensen, Simon , Bischof, Evelyne Y. , Bruening, Jens, Buchwalter, Abigail L. , Cabreiro, Filipe , Florian, Maria Carolina , Glass, David J. , Golato, Tyler, Gorbunova, Vera , Jäger, Sibylle , Kaeberlein, Matt R. , Karsenty, Gérard , Keizer, Peter L.J. de , Kennedy, Brian Keith , Kroemer, Guido , Liaskos, David, Partridge, Linda , Passegue, Emmanuelle A. , Petr, Michael Angelo , Rando, Thomas A. , Rudolph, K. Lenhard , Ai, Ruixue , Serrano, Manuel , Sinclair, David , Suh, Yousin , Taub, Pam R. , Verdin, Eric , Vijg, Jan , Westendorp, Rudi G. J. , Zonari, Alessandra Arcoverde Cavalcanti , Bakula, Daniela , Scheibye‐Knudsen, Morten

Mayo Clinic

Aging | January 28, 2022 | Volume: 14 | Issue: 2 | Pages: 530-543

10.18632/aging.203859 Get It

A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (AFT-41)
O’Donnell, Elizabeth , Geyer, Susan M. , Dinner, Shira, Laubach, Jacob P. , Mo, Clifton C. , Donadio, Kristen, Sinclair, Sarah, Richardson, Paul G. , Suman, Vera J. , Nadeem, Omar , Yee, Andrew J , Tuchman, Sascha Alexander , Raje, Noopur , Richardson, Paul Gerard Guy

Mayo Clinic

Blood | November 23, 2021 | Volume: 138 | Issue: Supplement 1 | Pages: 4776-4776

10.1182/blood-2021-146274 Get It

Abstract Background: Clinical data support the combination of an immunomodulatory drug, a proteasome inhibitor, and a glucocorticoid for the treatment of newly diagnosed multiple myeloma (NDMM). The combination of lenalidomide, bortezomib, and low-dose dexamethasone is a very active, well-tolerated standard of care in the transplant-ineligible NDMM population. Ixazomib, an oral proteasome inhibitor is approved by the US Food and Drug Administration in combination with lenalidomide and dexamethasone for the treatment of relapsed MM. Given that ixazomib has improved binding kinetics and pharmacologic profile compared with bortezomib, it is expected that these differences will translate into similar, if not improved, efficacy and safety profiles in the upfront setting. A phase l/ll study of lenalidomide, ixazomib, and dexamethasone in previously untreated patients with MM demonstrated that this combination was well-tolerated and active (NCT01217957). More recently, the GRIFFIN study evaluated the addition of the anti-CD38 monoclonal antibody, daratumumab to lenalidomide, bortezomib, and dexamethasone in transplant-eligible NDMM and demonstrated the ability of daratumumab to improve efficacy of the three-drug combination with an acceptable safety profile. Building upon these data, our study evaluates the addition of daratumumab to the all-oral regimen of lenalidomide, ixazomib, and dexamethasone in transplant-ineligible NDMM. The combination proposed in this study has been evaluated in NDMM irrespective of transplant eligibility and has demonstrated excellent efficacy and tolerability. Responses were rapid with 88% achieving a partial response (PR) or better after 2 cycles (33% very good partial response (VGPR) and 52% VGPR for 29 patients who had completed 4 cycles) with an overall response rate of 95%. 1 In our study, transplant-ineligible NDMM patients will be randomized to receive 12 cycles of induction with lenalidomide, ixazomib, dexamethasone, and daratumumab followed by lenalidomide alone versus lenalidomide, ixazomib, and daratumumab. Study Design and Methods: A randomized, phase II clinical trial (NCT04009109) is being conducted to assess the impact on progression-free survival (PFS) of the addition of ixazomib and daratumumab to lenalidomide as maintenance treatment following induction with lenalidomide, ixazomib, dexamethasone, and daratumumab. In this ongoing trial, eligible patients are randomized 1:1 to Arm A (12 cycles of lenalidomide, ixazomib, dexamethasone, and daratumumab followed by lenalidomide until disease progression or unacceptable toxicity or a maximum of 2 years of maintenance therapy) vs. Arm B (12 cycles of lenalidomide, ixazomib, dexamethasone, and daratumumab, followed by lenalidomide, ixazomib, and daratumumab until disease progression or unacceptable toxicity or a maximum of 2 years maintenance therapy). Eligible patients have NDMM requiring treatment, are ≥18 years, have ECOG PS of 0-2, and must have been deemed ineligible for stem cell transplantation. The primary endpoint is PFS. With a sample size of 188 patients (94 patients per arm) enrolled over a 36-month period and followed for a minimum of 24 months after the close of enrollment, a one-sided alpha=0.10 log rank test will have an 85% chance of detecting an increase in median PFS time from 30 months to 48 months (a hazard ratio of 0.625) with the addition of ixazomib and daratumumab to lenalidomide as a maintenance treatment following induction with ixazomib, lenalidomide, dexamethasone, and daratumumab. Secondary outcomes of interest include minimal residual disease, overall survival, changes in body composition, quality of life, psychosocial measures of functional status including social activity and support, psychological state, and nutrition using a geriatric assessment tool, and the association of these psychosocial measures with therapy-associated toxicities. 1Kapoor et al. Blood (2019) 134 (Supplement_1): 864. Support: Alliance Foundation Trials; Janssen, Takeda, Celgene; https://acknowledgments.alliancefound.org Figure 1 Figure 1. Disclosures O'Donnell: Bristol Myer Squibb: Consultancy; Janssen: Consultancy; Takeda: Consultancy; Oncopeptide: Consultancy; Adaptive: Consultancy; Karyopharm: Consultancy. Nadeem: GSK: Consultancy; Karyopharm: Consultancy; Adaptive: Consultancy; Takeda: Consultancy; Bristol Myer Squibb: Consultancy. Dinner: Kite/Gilead: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria. Yee: Takeda: Consultancy; Sanofi: Consultancy; Bristol Myers Squibb: Consultancy; Oncopeptides: Consultancy; Janssen: Consultancy; Karyopharm: Consultancy; Amgen: Consultancy; Adaptive: Consultancy; GSK: Consultancy. Mo: Karyopharm: Honoraria, Membership on an entity's Board of Directors or advisory committees; Epizyme: Consultancy; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; Eli Lilly: Consultancy. Tuchman: Karyopharm: Research Funding; Shattuck Labs: Consultancy; Sanofi / Genzyme: Consultancy, Research Funding; Caelum: Consultancy, Research Funding; Oncopeptides: Consultancy. Raje: Caribou: Other; Janssen: Other; bluebird bio: Other; Amgen: Other; Celgene: Other; BMS: Other. Richardson: AstraZeneca: Consultancy; Regeneron: Consultancy; Janssen: Consultancy; Celgene/BMS: Consultancy, Research Funding; Takeda: Consultancy, Research Funding; Oncopeptides: Consultancy, Research Funding; GlaxoSmithKline: Consultancy; Secura Bio: Consultancy; Sanofi: Consultancy; Protocol Intelligence: Consultancy; Karyopharm: Consultancy, Research Funding; AbbVie: Consultancy; Jazz Pharmaceuticals: Consultancy, Research Funding.
A Survey of American Thyroid Association Members Regarding the 2015 Adult Thyroid Nodule and Differentiated Thyroid Cancer Clinical Practice Guidelines
Sawka, Anna M. , Gagliardi, Anna R. , Haymart, Megan R. , Bernet, Victor , Hoff, Kelly, Brito, Juan P. , Haugen, Bryan R. , Kim, Brian W. , Kopp, Peter , Mandel, Susan J., Ross, Douglas S. , Sarne, David , Sinclair, Catherine F. , Jonklaas, Jacqueline , Brito, Juan P , Sturgeon, Cord , Angelos, Peter , Samuels, Mary H. , Sarne, David

Mayo Clinic

Thyroid® | December 13, 2019 | Volume: 30 | Issue: 1 | Pages: 25-33

10.1089/thy.2019.0486 | PMID 31830853 Get It

Background: The 2015 American Thyroid Association (ATA) clinical practice guidelines (CPGs) on management of thyroid nodules (TNs) and differentiated thyroid cancer (DTC) in adults were developed to inform clinicians, patients, researchers, and health policy makers about the best available evidence, and its limitations, relating to management of these conditions. Methods: We conducted a cross-sectional electronic survey of ATA members' perspectives of these CPGs, using a standardized survey (Clinician Guidelines Determinant Questionnaire) developed by the Guidelines International Network. A survey link was electronically mailed to members in February of 2019, with reminders sent to nonrespondents 2 and 5 weeks later. Data were descriptively summarized, after excluding missing responses. Results: The overall response rate was 19.8% (348/1761). The effective response rate was 20.2% (348/1720), after excluding a recently deceased member and individuals who had either invalid e-mail addresses or whose e-mails were returned. Of the respondents, 37.9% (132/348) were female, 60.4% (209/346) were endocrinologists, 27.5% (95/346) were surgeons, and 3.5% (12/346) were nuclear medicine specialists. The majority of respondents (71.9%; 250/348) were at a mid- or advanced-career level, and more than half were in academia (57.5%; 195/339). The majority (69.8%; 243/348) practiced in North America. The vast majority of respondents indicated that the CPGs explained the underlying evidence (92.3%; 298/323) and 92.9% (300/323) agreed or strongly agreed with the content. Most respondents stated that they regularly used the CPGs in their practice (83.0%; 268/323). Most respondents (83.0%; 268/323) also agreed or strongly agreed that the recommendations were easy to incorporate in their practice. The most popular CPG format was an electronic desktop file (78.8%; 252/320). Shorter more frequent CPGs were favored by 55.0% (176/320) of respondents, and longer traditional CPGs were favored by 39.7% (127/320). Conclusions: The clinical content and evidence explanations in the adult TN and DTC CPGs are widely accepted and applied among ATA survey respondents. Future ATA CPG updates need to be optimized to best meet users' preferences regarding format, frequency, and length.
Does Declining Mitochondrial NAD+ and Unscheduled Opening of Mitochondrial Transition Pore Promote Mammalian Aging?
Hafner, Angela, Gomes, Ana P. , Liang, Jing , Nair, Sree, Sauve, Anthony A. , Rozenzweig, Anthony, Sinclair, David , Liang, Jing, Cen, Yana , Lanza, Ian R.

Mayo Clinic

Blood | October 12, 2019 | Volume: 116 | Issue: 21 | Pages: SCI-3-SCI-3

10.1182/blood.v116.21.sci-3.sci-3 Get It

Abstract Abstract SCI-3 The processes that lead to the susceptibility of post-mitotic tissues to diseases of aging are poorly understood, but mitochondria are considered a key regulator. SIRT3 is mitochondrial sirtuin, a member a family of NAD+-dependent deacetylases. We have previously shown that increased levels of NAD+ in mitochondria promote cell survival in a SIRT3-dependent manner, but how this protection is mediated is unknown. Here we show that mitochondrial NAD+ levels decline dramatically with age and that SIRT3 is a critical component and regulator of the mitochondrial transition pore (MTP). Mice lacking SIRT3 exhibit hyperacetylation of the MTP with age, and as a result, develop multiple defects in post-mitotic tissues as they age, including mitochondrial defects, susceptibility to cardiac failure, and learning and memory deficits. In a mouse model of Alzheimer's disease (AD), SIRT3 knockout mice show striking phenotypes including small size, kyphosis, and a markedly reduced lifespan. Similar to mice, human brain samples show that acetylation of the MTP increases with age and with AD. These findings indicate that declining NAD levels with age lead to memory deficits and accelerate age-related diseases in post-mitotic tissues due to a decline in SIRT3 activity and unscheduled opening of the MTP. Disclosures: Sinclair: GlaxoSmithKline: Consultancy, Equity Ownership, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties.
Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline
LeRoith, Derek, Biessels, Geert Jan , Braithwaite, Susan S., Draznin, Boris , Halter, Jeffrey B., McDonnell, Marie E. , Molitch, Mark E. , Murad, M. Hassan , Murad, M Hassan , McDonnell, Marie E , Biessels, Geert Jan , Casanueva, Felipe F. , Hirsch, Irl B. , Sinclair, Alan J.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | March 23, 2019 | Volume: 104 | Issue: 5 | Pages: 1520-1574

10.1210/jc.2019-00198 | PMID 30903688 Get It

Abstract Objective The objective is to formulate clinical practice guidelines for the treatment of diabetes in older adults. Conclusions Diabetes, particularly type 2, is becoming more prevalent in the general population, especially in individuals over the age of 65 years. The underlying pathophysiology of the disease in these patients is exacerbated by the direct effects of aging on metabolic regulation. Similarly, aging effects interact with diabetes to accelerate the progression of many common diabetes complications. Each section in this guideline covers all aspects of the etiology and available evidence, primarily from controlled trials, on therapeutic options and outcomes in this population. The goal is to give guidance to practicing health care providers that will benefit patients with diabetes (both type 1 and type 2), paying particular attention to avoiding unnecessary and/or harmful adverse effects.